|
Synonyms: ALD-403 | ALD403 | eptinezumab-jjmr | Vyepti®
eptinezumab is an approved drug (FDA (2020), EMA (2022))
Compound class:
Antibody
Comment: Eptinezumab is a humanized IgG1 anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the prevention of migraine [6]. It was developed by Lundbeck and their subsidiary Alder Biopharmaceuticals (Alderbio). The INN record for eptinezumab indicates that it binds to CALCA (α-CGRP) and CALCB (β-CGRP). Peptide sequence alignment using NCBI BLAST Protein reveals 100% matches with sequences claimed in Alderbio's patent WO2012162257A2, and distinguish eptinezumab as the monoclonal referred to as Ab5 in the patent document.
CGRP plays an important role in migraine pathophysiology [2], and both the CGRP peptide and its receptor (CGRPR) are targets of anti-migraine therapeutics [1,4-5]. Eptinezumab is the fourth anti-CGRP pathway monoclonal to reach the clinic: the others are erenumab (anti-CGRPR), galcanezumab (anti-CALCA/B) and fremanezumab (anti-CALCA/B). These antibodies are used as alternatives to CGRPR antagonists such as ubrogepant (FDA approved in 2019). |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA (2020), EMA (2022)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10308 | eptinezumab |
| Synonyms |
| ALD-403 | ALD403 | eptinezumab-jjmr | Vyepti® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 648 |
| Other databases | |
| GtoPdb PubChem SID | 404859141 |
| Search PubMed clinical trials | eptinezumab |
| Search PubMed titles | eptinezumab |
| Search PubMed titles/abstracts | eptinezumab |
